Silexion Therapeutics Ltd.
SLXN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $5,815 | $3,708 | $3,226 | $0 |
| G&A Expenses | $6,731 | $928 | $577 | $0 |
| SG&A Expenses | $6,731 | $928 | $577 | $944 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $25 | $45 | $57 | $0 |
| Operating Expenses | $12,571 | $4,681 | $3,860 | $944 |
| Operating Income | -$12,571 | -$4,681 | -$3,860 | -$944 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$3,938 | -$395 | $396 | $189 |
| Pre-Tax Income | -$16,509 | -$5,076 | -$3,464 | -$755 |
| Tax Expense | $10 | $32 | $24 | $0 |
| Net Income | -$16,443 | -$4,942 | -$3,215 | -$755 |
| % Margin | – | – | – | – |
| EPS | -2.64 | -4.42 | 0.035 | -0.046 |
| % Growth | 40.3% | -12,764.8% | 176.2% | – |
| EPS Diluted | -2.64 | -4.42 | 0.035 | -0.046 |
| Weighted Avg Shares Out | 6,238 | 1,117 | 16,728 | 16,506 |
| Weighted Avg Shares Out Dil | 6,238 | 1,117 | 16,728 | 16,506 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $153 | $114 | $6 |
| Interest Expense | $52 | $9 | $85 | $0 |
| Depreciation & Amortization | $25 | $45 | $57 | $0 |
| EBITDA | -$16,477 | -$4,636 | -$3,803 | -$755 |
| % Margin | – | – | – | – |